Sirolimus in pediatric renal transplantation.

摘要: SRL, an mTOR inhibitor that inhibits cell cycle progression, represents important alternative to CNIs, which are still the cornerstones of pediatric solid organ tx. Because there limited data on SRL use among recipients, further studies needed verify efficacy and safety SRL. It has unique pharmacokinetic characteristics concerning dosing intervals reduction dose in combination with other immunosuppressants. also antineoplastic, antiviral, antiatherogenic advantages over immunosuppressive agents. The adverse effects including thrombocytopenia, hyperlipidemia, proteinuria, impaired wound healing, mouth ulcers, edema, male hypogonadism, TMA, interstitial pneumonitis must be considered carefully population. This article reviews most recent application field renal